Gene therapy shows promise for blinding eye disease
NCT ID NCT05903794
First seen Apr 24, 2026 · Last updated May 19, 2026 · Updated 4 times
Summary
This early-stage study tested a new gene therapy, EXG102-031, in 12 people with wet age-related macular degeneration (nAMD), a condition that causes blurry or lost central vision due to leaky blood vessels. The main goal was to see if the treatment is safe and tolerable. The therapy aims to block abnormal blood vessel growth to prevent further vision loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (NAMD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Erie Retina Research
Erie, Pennsylvania, 16507, United States
-
Sierra Eye Associates
Reno, Nevada, 89502, United States
Conditions
Explore the condition pages connected to this study.